Clover Biopharmaceuticals, Ltd.
HKEX:2197.HK
0.218 (HKD) • At close September 19, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) HKD.
| 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 19.499 | 19.499 | 0.129 | 0.129 | 0 | 0 | 7.442 | 7.442 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 237.757 | 237.757 | 618.453 | 618.453 | 241.543 | 241.543 | 3.721 | 3.721 | 33.133 | 33.133 | 0 | 0 |
| Gross Profit
| -218.258 | -218.258 | -618.325 | -618.325 | -241.543 | -241.543 | 3.721 | 3.721 | -33.133 | -33.133 | 0 | 0 |
| Gross Profit Ratio
| -11.193 | -11.193 | -4,811.864 | -4,811.864 | 0 | 0 | 0.5 | 0.5 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 132.141 | 132.141 | 192.802 | 192.802 | 305.03 | 305.03 | 427.633 | 427.633 | 596.23 | 596.23 | 316.921 | 316.921 |
| General & Administrative Expenses
| 44.674 | 44.674 | 54.734 | 54.734 | 92.447 | 92.447 | 112.672 | 112.672 | 110.454 | 110.454 | 62.401 | 62.401 |
| Selling & Marketing Expenses
| 16.128 | 16.128 | 11.256 | 11.256 | 105.514 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 60.802 | 60.802 | 65.99 | 65.99 | 92.447 | 92.447 | 112.672 | 112.672 | 110.454 | 110.454 | 62.401 | 62.401 |
| Other Expenses
| 0 | 0 | -1,398.881 | 0 | -495.165 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 175.987 | 175.987 | 944.602 | 944.602 | 416.418 | 416.418 | 573.001 | 573.001 | 2,320.871 | 2,320.871 | 655.484 | 655.484 |
| Operating Income
| -420.366 | -420.366 | -880.243 | -880.243 | -645.765 | -645.765 | -554.343 | -554.343 | -740.017 | -740.017 | -379.339 | -379.339 |
| Operating Income Ratio
| -21.558 | -21.558 | -6,850.14 | -6,850.14 | 0 | 0 | -74.488 | -74.488 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 25.785 | 25.785 | 1,205.555 | 1,205.555 | -12.145 | -12.145 | -13.7 | -13.7 | -1,610.76 | -1,610.76 | -278.037 | -278.037 |
| Income Before Tax
| -394.582 | -394.582 | 325.312 | 325.312 | -657.909 | -657.909 | -568.043 | -568.043 | -2,350.777 | -2,350.777 | -657.375 | -657.375 |
| Income Before Tax Ratio
| -20.236 | -20.236 | 2,531.611 | 2,531.611 | 0 | 0 | -76.329 | -76.329 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income
| -394.582 | -394.582 | 325.312 | 325.312 | -657.909 | -657.909 | -568.043 | -568.043 | -2,350.777 | -2,350.777 | -657.375 | -657.375 |
| Net Income Ratio
| -20.236 | -20.236 | 2,531.611 | 2,531.611 | 0 | 0 | -76.329 | -76.329 | 0 | 0 | 0 | 0 |
| EPS
| -0.32 | -0.32 | 0.26 | 0.26 | -0.59 | -0.59 | -0.53 | -0.53 | -2.03 | -2.03 | -0.568 | -0.568 |
| EPS Diluted
| -0.32 | -0.32 | 0.26 | 0.26 | -0.59 | -0.59 | -0.52 | -0.52 | -2.03 | -2.03 | -0.568 | -0.568 |
| EBITDA
| -409.87 | -409.87 | -871.59 | -871.59 | -638.355 | -638.355 | -547.262 | -547.262 | -735.886 | -735.886 | -377.323 | -377.323 |
| EBITDA Ratio
| -21.02 | -21.02 | -6,782.798 | -6,782.798 | 0 | 0 | -73.537 | -73.537 | 0 | 0 | 0 | 0 |